Home » SIGA BEGINS SMALLPOX DRUG TRIAL
SIGA BEGINS SMALLPOX DRUG TRIAL
Siga Technologies has reported that its lead drug candidate, SIGA-246, has begun Phase I clinical trials. Based on animal testing to date, SIGA believes that this candidate is a potent therapeutic drug against smallpox. The study will examine the safety and pharmacokinetics of SIGA-246 at different dosages in healthy volunteers.
SIGA-246 has demonstrated significant antiviral activity in various animal models of poxvirus disease, including the complete protection of golden ground squirrels from lethal doses of monkeypox virus.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May